Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study

Although guidelines recommend inclusion of immune modulators in anti-tumor necrosis factor (TNF) initiation therapy for Crohn ’s disease (CD) or ulcerative colitis (UC), there are limited data on the incremental effectiveness of this treatment strategy from the real world.

Source: Clinical Gastroenterology and Hepatology - November 15, 2018 Category: Gastroenterology Authors: Laura E. Targownik, Eric I. Benchimol, Charles N. Bernstein, Harminder Singh, MSc; Lisa Lix, Aruni Tennakoon, Stella Leung, Antonio Avi ña, Stephanie Coward, Jennifer Jones, Gil Kaplan, Sanjay K. Murthy, Geoffrey C. Nguyen, Juan Nicolás Peña-Sánchez Source Type: research